Urtė Fultinavičiūtė
Reporter
Urtė has previously worked as a Healthcare Reporter at GlobalData Media, primarily writing for Clinical Trials Arena. She mostly focused on clinical trial data management, strategy, and regulatory updates as well as clinical trial data readouts and exclusive interviews with C-level pharma and biotech executives. Urtė holds an MA in International Journalism from City, University of London.
Latest From Urtė Fultinavičiūtė
Zydus Marks Biosimilar Entry Into Mexico With Bevacizumab Approval
Marketed as Bhava, Zydus’ bevacizumab rival to Roche’s Avastin begins the firm’s biosimilar journey in the Latin American country.
Lupin And Zentiva Snatch First Generic Raltegravir Approval In UK
The UK’s MHRA has approved the first generic raltegravir to treat HIV in adults and certain pediatric patients and deemed the drug interchangeable with the originator Isentress.
Endo En Route To NYSE With Common Stock Exchange Expected Later In 2024
Endo continues to stride its financial revival path, with the latest plans to list common stock on the NYSE. Also, the firm has just launched a generic tiopronin rival to Travere Therapeutics' Thiola.
Off-Patent Group Trio Aims To Secure Transatlantic Drug Supply
Three off-patent associations from both sides of the Atlantic want to strengthen their collaborative synergies and secure the supply of generics and biosimilars.
Off-Patent Group Trio Aims To Secure Transatlantic Drug Supply
Three off-patent associations from both sides of the Atlantic want to strengthen their collaborative synergies, securing the supply of generics and biosimilars.
Regulatory Recap: US Senate Passes Anti-Patent Thicket Bill, EU Council Debates Pharma Package
Generics Bulletin recaps the most recent regulatory news and updates from across the world.